- Home
- CIEN vs LEGN Comparison
CIEN vs LEGN Comparison
Compare CIEN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIEN
- LEGN
- Stock Information
- Founded
- CIEN 1992
- LEGN 2014
- Country
- CIEN United States
- LEGN United States
- Employees
- CIEN N/A
- LEGN N/A
- Industry
- CIEN Telecommunications Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CIEN Utilities
- LEGN Health Care
- Exchange
- CIEN Nasdaq
- LEGN Nasdaq
- Market Cap
- CIEN 10.2B
- LEGN 5.4B
- IPO Year
- CIEN 1997
- LEGN 2020
- Fundamental
- Price
- CIEN $77.91
- LEGN $38.96
- Analyst Decision
- CIEN Buy
- LEGN Strong Buy
- Analyst Count
- CIEN 14
- LEGN 12
- Target Price
- CIEN $82.62
- LEGN $73.91
- AVG Volume (30 Days)
- CIEN 2.1M
- LEGN 1.6M
- Earning Date
- CIEN 09-03-2025
- LEGN 08-08-2025
- Dividend Yield
- CIEN N/A
- LEGN N/A
- EPS Growth
- CIEN N/A
- LEGN N/A
- EPS
- CIEN 0.73
- LEGN N/A
- Revenue
- CIEN $4,264,558,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CIEN $16.34
- LEGN $65.49
- Revenue Next Year
- CIEN $9.74
- LEGN $53.76
- P/E Ratio
- CIEN $106.51
- LEGN N/A
- Revenue Growth
- CIEN 2.86
- LEGN 112.46
- 52 Week Low
- CIEN $44.89
- LEGN $27.34
- 52 Week High
- CIEN $101.44
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CIEN 48.91
- LEGN 66.26
- Support Level
- CIEN $77.11
- LEGN $34.64
- Resistance Level
- CIEN $81.84
- LEGN $39.88
- Average True Range (ATR)
- CIEN 2.17
- LEGN 1.46
- MACD
- CIEN -0.21
- LEGN 0.37
- Stochastic Oscillator
- CIEN 41.83
- LEGN 87.67
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.